172 related articles for article (PubMed ID: 28919583)
1. Polyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro.
Hosseini Ghatar R; Soltantoyeh T; Bahadori M; Khoshnoodi J; Golsaz Shirazi F; Jeddi Tehrani M; Amiri MM; Shokri F
Iran J Immunol; 2017 Sep; 14(3):200-214. PubMed ID: 28919583
[TBL] [Abstract][Full Text] [Related]
2. Antibody Response to Human Extracellular HER2 Subdomain Proteins in Mice.
Sadri-Ardalani F; Ahmadi M; Hemmati A; Emami S; Farid S; Amiri MM; Jeddi-Tehrani M; Shabani M; Shokri F
Iran J Immunol; 2017 Jun; 14(2):99-110. PubMed ID: 28630381
[TBL] [Abstract][Full Text] [Related]
3. Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.
Sadri-Ardalani F; Shabani M; Amiri MM; Bahadori M; Emami S; Sarrafzadeh AR; Noutash-Haghighat F; Jeddi-Tehrani M; Shokri F
Tumour Biol; 2016 Jan; 37(1):1217-27. PubMed ID: 26282003
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory Effect of Polyclonal Antibodies Against HER3 Extracellular Subdomains on Breast Cancer Cell Lines.
Mansouri-Fard S; Ghaedi M; Shokri MR; Bahadori T; Khoshnoodi J; Golsaz-Shirazi F; Jeddi-Tehrani M; Amiri MM; Shokri F
Asian Pac J Cancer Prev; 2020 Feb; 21(2):439-447. PubMed ID: 32102522
[TBL] [Abstract][Full Text] [Related]
5. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
[TBL] [Abstract][Full Text] [Related]
6. A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity.
Deng W; Liu J; Pan H; Li L; Zhou C; Wang X; Shu R; Dong B; Cao D; Li Q; Wang Z
J Immunother; 2018 Jan; 41(1):1-8. PubMed ID: 29232309
[TBL] [Abstract][Full Text] [Related]
7. Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies.
Rockberg J; Schwenk JM; Uhlén M
Mol Oncol; 2009 Jun; 3(3):238-47. PubMed ID: 19393584
[TBL] [Abstract][Full Text] [Related]
8. Development of a Novel Inhibitory Chimeric Anti-HER2 Monoclonal Antibody.
Amiri MM; Bahadori T; Soltantoyeh T; Hosseini-Ghatar R; Golsaz-Shirazi F; Jeddi-Tehrani M; Shokri F
Iran J Immunol; 2019 Mar; 16(1):26-42. PubMed ID: 30864553
[TBL] [Abstract][Full Text] [Related]
9. Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance.
Pedersen MW; Jacobsen HJ; Koefoed K; Dahlman A; Kjær I; Poulsen TT; Meijer PJ; Nielsen LS; Horak ID; Lantto J; Kragh M
Mol Cancer Ther; 2015 Mar; 14(3):669-80. PubMed ID: 25612619
[TBL] [Abstract][Full Text] [Related]
10. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
11. Epitope Mapping of Human HER2 Specific Mouse Monoclonal Antibodies Using Recombinant Extracellular Subdomains.
Hosseini Ghatar R; Soltantoyeh T; Bahadori T; Golara M; Hassannia H; Khosravi Eghbal R; Khoshnoodi J; Judaki MA; Golsaz-Shirazi F; Jeddi-Tehrani M; Amiri MM; Shokri F
Asian Pac J Cancer Prev; 2017 Nov; 18(11):3103-3110. PubMed ID: 29172286
[TBL] [Abstract][Full Text] [Related]
12. Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition.
Amiri MM; Golsaz-Shirazi F; Soltantoyeh T; Hosseini-Ghatar R; Bahadori T; Khoshnoodi J; Navabi SS; Farid S; Karimi-Jafari MH; Jeddi-Tehrani M; Shokri F
Invest New Drugs; 2018 Apr; 36(2):171-186. PubMed ID: 28983766
[TBL] [Abstract][Full Text] [Related]
13. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody.
Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B
MAbs; 2018; 10(6):864-875. PubMed ID: 30081724
[TBL] [Abstract][Full Text] [Related]
14. The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.
Shin JW; Kim S; Ha S; Choi B; Kim S; Im SA; Yoon TY; Chung J
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31635022
[TBL] [Abstract][Full Text] [Related]
15. HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design.
de Goeij BE; Peipp M; de Haij S; van den Brink EN; Kellner C; Riedl T; de Jong R; Vink T; Strumane K; Bleeker WK; Parren PW
MAbs; 2014; 6(2):392-402. PubMed ID: 24492309
[TBL] [Abstract][Full Text] [Related]
16. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
17. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Carvajal-Hausdorf DE; Schalper KA; Bai Y; Black J; Santin AD; Rimm DL
Gynecol Oncol; 2017 Apr; 145(1):154-158. PubMed ID: 28196634
[TBL] [Abstract][Full Text] [Related]
18. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
Ghedini GC; Ciravolo V; Tortoreto M; Giuffrè S; Bianchi F; Campiglio M; Mortarino M; Figini M; Coliva A; Carcangiu ML; Zambetti M; Piazza T; Ferrini S; Ménard S; Tagliabue E; Pupa SM
J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
[TBL] [Abstract][Full Text] [Related]
19. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
[TBL] [Abstract][Full Text] [Related]
20. Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex.
Hao Y; Yu X; Bai Y; McBride HJ; Huang X
PLoS One; 2019; 14(5):e0216095. PubMed ID: 31042744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
